Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors

NCT02476123 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

BIOLOGICAL: Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)

Sponsor

Kyowa Kirin Co., Ltd.

Collaborators

[object Object]